Table 3.

Response of lung adenocarcinoma patients to RET tyrosine kinase inhibitors

Patient	RET fusion gene	Inhibitor	Ethnicity	Sex	Age, years	Pathological diagnosis	Smoking history (pack‐year)	Response (% decrease)	Reference
1	TRIM33–RET	Cabozantinib	Caucasian	Female	41	Papillary adenocarcinoma	Never‐smoker	Partial response (66)	16
2	KIF5B–RET	Cabozantinib	African‐American	Female	75	Poorly differentiated adenocarcinoma	Never‐smoker	Partial response (32)	16
3	KIF5B–RET	Cabozantinib	Caucasian	Female	68	Mixed subtype adenocarcinoma	Never‐smoker	Stable disease	16
4	KIF5B–RET	Vandetanib	Caucasian	Male	58	Poorly differentiated adenocarcinoma	Former smoker (5)	Decrease in size	26